# Lewis Pell

> Lewis Pell is a post-ipo equity investor backing Health Care and Medical. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Location: Horsham, United States
- Total investments: 2
- Last investment: Nov 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lewis-pell-a9216810

Lewis Pell is a post-ipo equity investor in Horsham focused on Health Care and Medical. Lewis Pell was appointed to our Board of Directors and was unanimously elected to serve as Non-Executive Chairman of the Board on December 12, 2011. Pell was a member of Radiancy’s Board since 1998. Pell has founded over a dozen successful medical technology companies during the past three decades. In 1979, he founded Pentax PrecisionInstruments, which was sold to Asahi Optical Co. in 1990. In 1983, he founded American Endoscopy Inc., which was sold to C.R. Bard, Inc. (BCR-NYSE) in 1986. In 1984, he founded Versaflex Inc., which was sold to Medtronic in 1988. In 1989, he founded Heart Technology Corp., which went public in the U.S. in 1992 and was sold to Boston Scientific Corp. (BSX-NYSE) in 1995. In 1991, he founded InStent Inc., which became a public company in 1995 and was sold to Medtronic in 1996. In 1994, he founded Influence Inc., which was sold to American Medical Systems Inc. in 1999. Working with Shlomo Ben-Haim, Pell founded Biosense Inc. in 1994, which was sold to Johnson & Johnson in 1997. He is currently chairman and an investor for a number of private medical device companies. In 1992, he founded and remains the chairman of Vision-Sciences, Inc. (VSCI-NASDAQ). Pell has a B.S. in political science from Brooklyn College and over 20 years of experience in the medical technology industry. Pell was selected to serve on the Company’s board because of his over thirty-years’ experience in leadership roles in the medical device industry.

## Contacts

5 contacts available for Lewis Pell: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/lewis-pell?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Medical | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vensica Medical | Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $16M | Venture - Series Unknown | Nov 01, 2021 | http://vensica.com/ |
| Vision Sciences | Vision-Sciences, Inc., is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes,otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation. | $10.5M | Post-IPO Equity | Feb 01, 2011 | http://www.visionsciences.com/ |

2 of 2 investments shown.

## Co-investors
- [Agriline](https://shizune.co/investors/profile/agriline) — VC Fund, 1 deal together
- [Israel Biotech Fund](https://shizune.co/investors/profile/israel-biotechfund) — VC Fund, 1 deal together
- [Laborie Medical Technologies](https://shizune.co/investors/profile/laborie-medical-technologies) — VC Fund, 1 deal together
- [Trendlines Group](https://shizune.co/investors/profile/trendlines-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Medical Device Angel Investors in Israel](https://shizune.co/investors/medical-device-angel-investors-israel)
- [Health Care Angel Investors in Middle East](https://shizune.co/investors/health-care-angel-investors-middle-east)
- [Health Care Angel Investors in Israel](https://shizune.co/investors/health-care-angel-investors-israel)

## FAQ

### What does Lewis Pell invest in?

Lewis Pell invests primarily in Health Care, Medical and Therapeutics startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lewis Pell?

Public channels for Lewis Pell include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Lewis Pell last invest?

The most recent investment recorded for Lewis Pell closed in Nov 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co